Features Partner Sites Information LinkXpress
Sign In
Demo Company

New Kit Enables Rapid PCR on Whole Blood Samples

By BiotechDaily International staff writers
Posted on 02 Dec 2013
Print article
A new kit is now available that allows biotech and other life science researchers to easily perform PCR (polymerase chain reaction) analyses on whole blood samples.

The Bioline (London, United Kingdom) MyTaq Blood-PCR Kit was specifically engineered to overcome PCR inhibitors typically present in blood samples such as anticoagulants (EDTA, citrate, and heparin) and to give significantly increased sensitivity and success rates even with demanding applications such as GC-rich templates or longer amplicons.

The MyTaq Blood-PCR Kit enables very fast and highly specific direct PCR from a wide range of human and animal whole blood samples. Its novel buffer system eliminates the need for complicated extraction or purification steps or use of additives.

The advanced formulation of the MyTaq Blood-PCR Kit allows fast cycling conditions to be used, without compromising PCR specificity or yield. The addition of an inert red dye in the mix also helps improve throughput. The kit's speed and high specificity make it ideal for multiplex PCR and high-throughput genotyping assays.

Marco Calzavara, president of Bioline, said, "With MyTaq Blood-PCR Kit, researchers can now quickly and easily achieve the purity and yield necessary for high-performance PCR direct from mammalian blood samples. This makes MyTaq Blood-PCR Kit the perfect complement to our widely used PCR reagents.”

Bioline is a wholly owned subsidiary of Meridian Life Science, Inc. (Cincinnati, OH, USA).

Richard L. Eberly, president of Meridian Life Science, Inc., said, "We are delighted to release the MyTaq Blood-PCR Kit which simplifies the process of PCR extractions from whole blood samples. We are committed to our life science customers and to bringing innovation and quality products; such as the MyTaq Blood-PCR Kits to the research laboratory, clinical diagnostic laboratories, and biotechnology companies."

Related Links:

Meridian Life Science, Inc.

Print article



view channel
Image: Left: Green actin fibers create architecture of the cell. Right: With cytochalasin D added, actin fibers disband and reform in the nuclei (Photo courtesy of the University of North Carolina).

Actin in the Nucleus Triggers a Process That Directs Stem Cells to Mature into Bone

A team of cell biologists has discovered why treatment of mesenchymal stem cells (MSCs) with the mycotoxin cytochalasin D directs them to mature into bone cells (osteoblasts) rather than into fat cells... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.